Connect Biopharma Holdings (CNTB) Research & Development (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted Research & Development of $15.0 million for Q1 2026, up 33.22% sequentially from $11.3 million in Q4 2025, and up 126.59% YoY from $6.6 million in Q1 2025.
Connect Biopharma Holdings (CNTB) Research & Development (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Research & Development for 3 years, with the latest figure at $15.0 million in Q1 2026.
- Quarterly Research & Development rose 126.59% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.2 million (up 69.67% YoY) and the FY2025 annual result came in at $37.8 million, up 29.2% from the prior year.
- Research & Development rose to $15.0 million in Q1 2026 per CNTB's latest filing, from $11.3 million in the prior quarter.
- Over five years, Research & Development peaked at $15.0 million in Q1 2026 and troughed at $5.3 million in Q2 2024.
- A 3-year average of $9.1 million and a median of $8.8 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2025 and 2026: Research & Development slipped 23.43% in 2025, then surged 126.59% in 2026.
- Over 3 years, Research & Development stood at $6.2 million in 2024, then soared by 80.92% to $11.3 million in 2025, then soared by 33.22% to $15.0 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $15.0 million, $11.3 million, and $11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Connect Biopharma Holdings | 144.32 Mn | 144.32 Mn | - | 16.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.27 Mn |
| Mar 31, 2026 | 15.03 Mn |
| Dec 31, 2025 | 11.28 Mn |
| Sep 30, 2025 | 11.11 Mn |
| Jun 30, 2025 | 8.77 Mn |
| Mar 31, 2025 | 6.63 Mn |
| Dec 31, 2024 | 6.24 Mn |
| Sep 30, 2024 | 9.01 Mn |
| Jun 30, 2024 | 5.35 Mn |
| Mar 31, 2024 | 8.66 Mn |